February 12, 2016
Chugai Pharmaceutical said on February 10 that its Japanese PIII trial on Alecensa (alectinib) enrolling patients with ALK fusion gene positive non-small cell lung cancer (NSCLC) was stopped early after it achieved the primary endpoint at a pre-planned interim analysis...read more